INVITATION
Dear Colleagues,
Turkish and British Associations for the Study of Liver (TASL-BASL) are pleased to announce a digital monothematic conference, “Drug-induced Liver Injury: Unresolved questions and unmet needs” on March 12-13, 2021. We hope that the programme will be a timely and welcome opportunity to reflect upon an area of critical importance for clinicians, researchers, scientists, pharma and other health care professionals.
Drugs and herbs are a common aetiology underlying acute liver injury. The number, variety and mechanism of action of drugs in use continues to expand. Along with this, interest and importance of drug-induced liver injury (DILI) has grown. Dissemination of knowledge related to DILI and a shared understanding is crucial to improve its diagnosis and safety of medications.
On behalf of TASL and BASL, we welcome you to join experts from Turkey and the United Kingdom in this event where we aim to appraise recent advances and emerging context in the field to identify priorities for future collaboration. We are excited to have this opportunity to create a partnership between TASL and BASL as well as to share the cutting-edge information with regards to DILI.
We look forward to seeing you all,
Prof. Guruprasad Aithal
President, BASL
Prof. Ramazan Idilman
President, TASL
BASL Organizer
Guruprasad Aithal
TASL Organizer
Fulya Gunsar
Scientific Secretariat
-
Cemal Nuri Erçin
Mujdat Zeybel
Gupse Adalı
MAIN TOPICS
Session 1: Hepatotoxicity: Epidemiology and pathogenesis
- Epidemiology – Pro- Euro- DILI network registry
- TASL-Hepatotoxicity Database
- Host and drug dependant risk factors for hepatotoxicity
- Mechanisms of injury and immune-mediated reactions
- Pharmacogenomics and DILI
Session 2: Clinical manifestations
- Clinical presentation and patterns of DILI
- Oral presentation
- Drug-induced autoimmune hepatitis
- Herbal and supplement-induced liver injury (HILI/SILI)
Session 3: The other presentations of hepatotoxicity
- Acute fatty liver and drug-associated fatty liver disease(with case)
- Liver toxicity due to treatments for COVİD(with case)
- Check point inhibitor induced liver injury (CHILI)
Session 4: Toxic hepatitis and drug-drug interaction during chronic viral hepatitis
- Toxic hepatitis and drug-drug interaction during HBV treatment
- Toxic hepatitis and drug-drug interaction during HCV treatment in the era of DAA
Session 5: Causality assessment and diagnosis of DILI
- Laboratory workup and imaging, Liver biopsy: when and whom?
- Causality assessment methods and diagnosis
- Liver histopathology
Session 6: Oral presentations of Selected Posters
Session 7: Severity and Prognosis of DILI
- What is coming as new biomarkers for DILI?
- Severity assessment and natural history chronic DILI
- Re-challenge, recurrent DILI (with case)
- Oral presentation
Session 8: Management in severe cases
- General measures and specific therapies
- Difficult decisions in management of severe DILI
- Controversies in severe DILI: From EASL guideline to clinical practice
Session 9: Drug-induced acute liver failure
- Mushroom poisoning and acute liver failure (with case)
- Management of drug-induced ALF
- Living donor liver transplant in drug-induced ALF
- Future for DILI: Unresolved questions and unmet needs
SCIENTIFIC PROGRAM
ABSTRACT
ABSTRACTS
All abstracts should be submitted electronically via the abstractModule submission system. The abstracts not submitted via the abstract system but via e-mail and regular post shall not be accepted. The abstracts submitted online shall be published without any correction; therefore the authors should be careful about spelling mistakes.
Abstract Submission Deadline 8 February 2021
Guidelines for Submission
- The abstracts shall be submitted only via the online abstract system.
- All abstracts should be written and presented in English.
- Names of the authors should not include their academic titles.
- The names should be written with only the first letter in capital and the rest in small letters and without abbreviation.
- Name and address of the institution, in which the author is employed, should be stated.
- Only the first letter of the abstract title should be in capital letters. (Abbreviations excluded.)
- In case abbreviation is used in the abstract, the abbreviation should be explained in parenthesis.
- The purpose of the paper and the methods applied should be explained in brief, the findings should be summarized together with sufficient statistical details and the conclusion should be stated within the framework of the findings presented.
- Abstract should be organized in a way to include the titles of objective, materials and methods, results and conclusions.
- The abstract length should not exceed 3000 characters excluding the abstract title, name and surname of the author.
Important Notices
- If you will use the online abstract module for the first time, select the “New User” link and register to the system.
- The explanations at the page after the registration procedure will guide you. Please read the messages and explanations carefully.
- The abstracts submitted via internet shall be published without any corrections; therefore the authors should be careful about spelling mistakes.
- Please keep the confirmation mail sent to your e-mail address following the abstract submission.
- You can track the evaluation process of your abstract over the system by using your e-mail and password.
- For technical assistance or questions during abstract submission contact Minduce IT Solutions Ltd. by emailing support@abstractmodule.com or calling phone: +90 216 410 44 14, 9:00 a.m. – 6:00 p.m. (EET), Monday-Friday.
